Association Between Empagliflozin Use and Electrocardiographic Changes

Overview

Journal Clin Pract

Publisher MDPI

Specialty General Medicine

Date 2022 Jul 27

PMID 35892445

Authors

Daniel Antwi-Amoabeng

Sunil Sathappan

Bryce D Beutler

Mark B Ulanja

Munadel Awad

Nageshwara Gullapalli

Phillip Duncan

T David Gbadebo

Affiliations

Soon will be listed here.

Abstract

Empagliflozin, a sodium-glucose transporter 2 inhibitor, has been shown to bind to late sodium channels in mice cardiomyocytes. We sought to investigate the electrocardiographic (ECG) features associated with empagliflozin use in patients with diabetes mellitus. We compared ECG features of 101 patients before and after initiation of empagliflozin and found that empagliflozin was associated with a significant increase in QRS duration among diabetes patients with heart failure.

Citing Articles

Impact of baseline ECG characteristics on changes in cardiac biomarkers and echocardiographic metrices after acute myocardial infarction treated with Empagliflozin.

Benedikt M, Aziz F, Froschl T, Strohhofer C, Kolesnik E, Tripolt N Sci Rep. 2024; 14(1):15083.

PMID: 38956086 PMC: 11219811. DOI: 10.1038/s41598-024-64175-5.

The Year 2022 in Cardiovascular Diseases-.

Abrignani M Clin Pract. 2023; 13(4):763-767.

PMID: 37489418 PMC: 10366779. DOI: 10.3390/clinpract13040069.

References

Curtain J, Docherty K, Jhund P, Petrie M, Inzucchi S, Kober L . Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF. Eur Heart J. 2021; 42(36):3727-3738. PMC: 8455345. DOI: 10.1093/eurheartj/ehab560. View

Yu S, Li G, Huang C, Lei M, Wu L . Late sodium current associated cardiac electrophysiological and mechanical dysfunction. Pflugers Arch. 2017; 470(3):461-469. DOI: 10.1007/s00424-017-2079-7. View

Fernandes G, Fernandes A, Cardoso R, Penalver J, Knijnik L, Mitrani R . Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: A meta-analysis of 34 randomized controlled trials. Heart Rhythm. 2021; 18(7):1098-1105. DOI: 10.1016/j.hrthm.2021.03.028. View

Zannad F, Ferreira J, Pocock S, Anker S, Butler J, Filippatos G . SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet. 2020; 396(10254):819-829. DOI: 10.1016/S0140-6736(20)31824-9. View

Jhuo S, Liu I, Tasi W, Chou T, Lin Y, Wu B . Characteristics of Ventricular Electrophysiological Substrates in Metabolic Mice Treated with Empagliflozin. Int J Mol Sci. 2021; 22(11). PMC: 8200966. DOI: 10.3390/ijms22116105. View

Chang S, Wu L, Chiou M, Liu J, Yu K, Kuo C . Association of metformin with lower atrial fibrillation risk among patients with type 2 diabetes mellitus: a population-based dynamic cohort and in vitro studies. Cardiovasc Diabetol. 2014; 13:123. PMC: 4149273. DOI: 10.1186/s12933-014-0123-x. View

Antzelevitch C, Nesterenko V, Shryock J, Rajamani S, Song Y, Belardinelli L . The role of late I Na in development of cardiac arrhythmias. Handb Exp Pharmacol. 2014; 221:137-68. PMC: 4076160. DOI: 10.1007/978-3-642-41588-3_7. View

Maier L . A novel mechanism for the treatment of angina, arrhythmias, and diastolic dysfunction: inhibition of late I(Na) using ranolazine. J Cardiovasc Pharmacol. 2009; 54(4):279-86. PMC: 4454281. DOI: 10.1097/FJC.0b013e3181a1b9e7. View

Grisanti L . Diabetes and Arrhythmias: Pathophysiology, Mechanisms and Therapeutic Outcomes. Front Physiol. 2018; 9:1669. PMC: 6275303. DOI: 10.3389/fphys.2018.01669. View

10.

Horvath B, Hezso T, Kiss D, Kistamas K, Magyar J, Nanasi P . Late Sodium Current Inhibitors as Potential Antiarrhythmic Agents. Front Pharmacol. 2020; 11:413. PMC: 7184885. DOI: 10.3389/fphar.2020.00413. View

11.

Whitbeck M, Charnigo R, Shah J, Morales G, Leung S, Fornwalt B . QRS duration predicts death and hospitalization among patients with atrial fibrillation irrespective of heart failure: evidence from the AFFIRM study. Europace. 2013; 16(6):803-11. PMC: 4305520. DOI: 10.1093/europace/eut335. View

12.

Huxley R, Filion K, Konety S, Alonso A . Meta-analysis of cohort and case-control studies of type 2 diabetes mellitus and risk of atrial fibrillation. Am J Cardiol. 2011; 108(1):56-62. PMC: 3181495. DOI: 10.1016/j.amjcard.2011.03.004. View

13.

Movahed M, Hashemzadeh M, Jamal M . Diabetes mellitus is a strong, independent risk for atrial fibrillation and flutter in addition to other cardiovascular disease. Int J Cardiol. 2005; 105(3):315-8. DOI: 10.1016/j.ijcard.2005.02.050. View

14.

Li W, Chen X, Xu L, Li Y, Luo B . SGLT2 inhibitors and atrial fibrillation in type 2 diabetes: a systematic review with meta-analysis of 16 randomized controlled trials. Cardiovasc Diabetol. 2020; 19(1):130. PMC: 7448518. DOI: 10.1186/s12933-020-01105-5. View

15.

Cardoso C, Salles G, Deccache W . Prognostic value of QT interval parameters in type 2 diabetes mellitus: results of a long-term follow-up prospective study. J Diabetes Complications. 2003; 17(4):169-78. DOI: 10.1016/s1056-8727(02)00206-4. View

16.

Packer M, Anker S, Butler J, Filippatos G, Pocock S, Carson P . Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020; 383(15):1413-1424. DOI: 10.1056/NEJMoa2022190. View

17.

Zelniker T, Bonaca M, Furtado R, Mosenzon O, Kuder J, Murphy S . Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial. Circulation. 2020; 141(15):1227-1234. DOI: 10.1161/CIRCULATIONAHA.119.044183. View

18.

Baycin-Hizal D, Gottschalk A, Jacobson E, Mai S, Wolozny D, Zhang H . Physiologic and pathophysiologic consequences of altered sialylation and glycosylation on ion channel function. Biochem Biophys Res Commun. 2014; 453(2):243-53. PMC: 4544737. DOI: 10.1016/j.bbrc.2014.06.067. View

19.

Lopaschuk G, Verma S . Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: A State-of-the-Art Review. JACC Basic Transl Sci. 2020; 5(6):632-644. PMC: 7315190. DOI: 10.1016/j.jacbts.2020.02.004. View

20.

Margraf-Schonfeld S, Bohm C, Watzl C . Glycosylation affects ligand binding and function of the activating natural killer cell receptor 2B4 (CD244) protein. J Biol Chem. 2011; 286(27):24142-9. PMC: 3129195. DOI: 10.1074/jbc.M111.225334. View